Boston Scientific Q2 Earnings: Strong Performance Of Cardiovascular Devices Leads To 2024 Guidance Hike Again
Boston Scientific Q2 Earnings: Strong Performance Of Cardiovascular Devices Leads To 2024 Guidance Hike Again
Boston Scientific Corporation (NYSE:BSX) generated second-quarter revenues of $4.12 billion, beating the consensus estimate of $4.02 billion.
波士頓科學公司（紐交所：BSX）第二季度營收爲412億美元，超過共識預估的402億美元。
Sales increased 14.5% on a reported basis, compared to the company's guidance range of 10.5%-12.5% and 16.1% on an operational basis, 14.7% on an organic basis, compared to the company's guidance range of 10%-12%.
報告顯示，公司營收按報告基礎增長14.5%，比公司指導範圍10.5%-12.5%高；按運營基礎增長16.1%，按有機基礎增長14.7%，比公司指導範圍10%-12%高。
The company earned an adjusted EPS of $0.62, beating the consensus of $0.58 and the management guidance of $0.57-$0.59.
公司調整後每股收益爲0.62美元，超過了預期的0.58美元和管理層預期的0.57美元至0.59美元。
Related: Boston Scientific's Upside With Cardiology Devices Drives Momentum.
相關報道：波士頓科學的心臟病診斷設備存在增長空間。
The company's cardiovascular segment generated sales of $2.64 billion, rising 17.8% (19.7% operationally and 19% organically).
該公司心血管事業部銷售額達到了264億美元，增長了17.8%（運營基礎和有機基礎均爲19.7%和19%）。
Boston Scientific reported 20.1% growth for cardiology products and 10.2% growth in peripheral interventions.
波士頓科學的心臟病產品增長了20.1%，周邊介入術增長了10.2%。
MedSurg segment revenues increased 9% to $1.48 billion (10.1% operationally and 7.6% organically).
醫療手術事業部營收增長9%，達到了148億美元（運營基礎和有機基礎分別增長10.1%和7.6%）。
Neuromodulation led the way with a 15.5% increase. Urology (8.2%) and Endoscopy (7.1%) followed.
神經調控市場領先，增長了15.5%。其次是泌尿外科（8.2%）和內窺鏡（7.1%）。
Outlook: Boston Scientific forecasts net sales growth for 2024 of approximately 13.5%-14.5% on a reported basis and 13%-14% on an organic basis, compared to prior guidance of 11%-13% and 10%-12%, respectively.
展望：波士頓科學公司預計2024年營收按報告基礎將增長約13.5%-14.5%，有機基礎將增長13%-14%，超過先前預期的分別爲11%-13%和10%-12%。
Boston Scientific estimates 2024 adjusted EPS of $2.38-$2.42 compared to prior guidance of $2.29-$2.34 and consensus of $2.33.
波士頓科學公司預計2024年調整後每股收益爲2.38-2.42美元，高於先前預期的2.29-2.34美元及市場預估的2.33美元。
For the third quarter, the company estimates net sales growth of 13%-14% on a reported and organic basis.
第三季度，公司預計營收按報告和有機基礎增長13%-14%。
The company forecasts adjusted EPS of $0.57-$0.59 versus a consensus of $0.57.
公司預計調整後每股收益爲0.57-0.59美元，市場預估爲0.57美元。
Price Action: BSX stock was trading lower by 1.95% at $77.05 at the last check on Wednesday.
週三最新數據顯示，BSX股票下跌1.95%，報收77.05美元。
- Boston Scientific Adds Stroke Prevention To Vascular Portfolio Via Silk Road Medical's $1.3B Deal.
- 通過對Silk Road Medical的13億美元收購，波士頓科學將卒中預防產品併入血管產品系列。
Photo via Shutterstock
圖片來自shutterstock。